Prostate Cancer Imaging with 18F-Fluciclovine

Diagnostic Accuracy of PET with 18F-Fluciclovine ([18F]FACBC) in Detecting High-Grade Gliomas: A Systematic Review and Meta-Analysis

“…To date, most clinical research on [ 18 F]FACBC PET has focused on prostate cancer due to the increased amino acid transport and [ 18 F]FACBC uptake by prostate cancer tumor cells. In this regard, evidence-based data reported a good diagnostic accuracy for [ 18 F]FACBC PET in detecting prostate cancer lesions [11,28]. However, [ 18 F]FACBC uptake is not specific to prostate cancer cells, as some benign lesions and malignant tumors, including gliomas, may take up this radiolabeled amino acid [29,30].…”

“…About gliomas, PET/CT and/or PET/MRI have two main fields of application: the ability to discriminate LGG and HGG and accuracy in detecting HGG recurrence differentiating residual/recurrent disease from treatment-related changes [6,7]. In this regard, different radiopharmaceuticals have been used, including several radiolabeled amino acid tracers (such as 11 C-methylmethionine ([ 11 C]MET), 18 F-fluoro-ethyl-tyrosine ([ 18 F]FET), and 18 F-dihydroxyphenylalanine ([ 18 F]FDOPA]) and fluorine-18 fluorodeoxyglucose ([ 18 F]FDG), with different performances and global good diagnostic accuracy [8,9]. Recently, some evidence also about the good diagnostic accuracy of Prostate Specific Membrane Antigen (PSMA)-targeting radiopharmaceuticals in HGG was described [10].…”

“…Synthetic non-metabolized leucine-derivate anti-1-amino-3-18 F-fluorocyclobutane-1carboxylic acid ( 18 F-Fluciclovine, [ 18 F]FACBC) is known to accumulate in prostate cancer tumor cells [11], but is not limited to prostate cancer. Beyond prostate cancer, [ 18 F]FACBC has been also been demonstrated to be highly accumulated in other solid tumors, including HGG [12].…”